Clinical trial registry record

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 10, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04270747
Last registry update
September 10, 2025
Status
Completed
Phase
Phase 3
Sponsor
Amgen
Enrollment
576
Countries
United States, Canada, Czechia, Estonia, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Poland, Serbia, Slovakia, South Korea, Spain
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
576
Population
ALL · 50 Years
Duration
2020-06-22 to 2023-01-30
Intervention
ABP 938; Aflibercept
Comparator
Aflibercept-Treatment Group B1; ABP 938-Treatment group B2
Outcomes measured
Mean Change From Baseline in BCVA at Week 8 — Baseline and Week 8; Percentage of Participants Who Maintained Vision at Week 52 — Week 52; Mean Change From Baseline in BCVA — Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52; Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8 — Week 8; Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52 — Week 52; Mean Change From Baseline in Choroidal Neovascularization (CNV) Area Size — Baseline and Weeks 8, 16, 24, and 52; Mean Change From Baseline in Central Subfield Thickness (CST) — Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52; Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Up to Week 52; Number of Participants Developing Binding Antidrug Antibodies (ADAs) — Baseline up to Week 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON